These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2284494)

  • 1. [The correlation between the serum concentrations of CA 549 and CA 15.3 in patients with cystic breast disease].
    Allende MT; Vizoso F; Fueyo A; Ruibal A
    Rev Clin Esp; 1990; 187(3):152-3. PubMed ID: 2284494
    [No Abstract]   [Full Text] [Related]  

  • 2. [Correlation between blood concentrations of CA 15.3 and estradiol in women with macrocystic disease of breast. Study in function of the type of cyst].
    Vizoso F; Allende MT; Díez MC; Ruibal A
    Rev Clin Esp; 1991 Nov; 189(8):390-1. PubMed ID: 1784805
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
    Bartel U; Johannsen B; Reiss H; Elling D
    Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlations of serum concentrations of CA 15.3 and estradiol in women with breast macrocystic disease].
    Vizoso F; Allende MT; Fueyo A; Vivanco J
    Med Clin (Barc); 1990 May; 94(20):798. PubMed ID: 2392013
    [No Abstract]   [Full Text] [Related]  

  • 6. [The correlation between the serum concentrations of BCM (breast cancer mucin), CA549 and estradiol in women with breast macrocysts].
    Vizoso F; Allende MT; Fueyo A; Ruibal A
    Med Clin (Barc); 1991 Feb; 96(5):198. PubMed ID: 2033998
    [No Abstract]   [Full Text] [Related]  

  • 7. [Correlation of serum concentrations of BCM and MCA, CA 549 and CA 15.3 in women with macrocystic disease of breast].
    Vizoso F; Roiz MC; Allende MT; Ruibal A
    Med Clin (Barc); 1990 Mar; 94(8):319. PubMed ID: 2342398
    [No Abstract]   [Full Text] [Related]  

  • 8. [The intracystic concentration of MCA in the fluid from large breast cysts].
    Mezi S; Reale MG; Aloise G; Marigliani A; Marchei CG; Sallusti E; Mentuccia D; Del Nero A; Izzo P; Modesti M
    G Chir; 1999 May; 20(5):246-51. PubMed ID: 10380368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between BCM (breast cancer mucin) and CA 549 serum levels cystic breast disease.
    Allende MT; Vizoso F; Roiz MC; Fueyo A; Ruibal A
    Int J Biol Markers; 1990; 5(1):48-9. PubMed ID: 2230352
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with CA 15.3 as a tumor marker in breast cancer.
    Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
    Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tumor markers in patients with breast cancer.
    Lumachi F; Basso SM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
    Suzuki M; Sekiguchi I; Tamada T
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
    Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
    Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carcinoma.
    Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Casaldi V; Cavaliere F; Carlini M; Garofalo A; Rinaldi G
    Anticancer Res; 1993; 13(6B):2409-13. PubMed ID: 8135475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.